Hyoscyamine Sulfate Solution 0.125 mg/mL: Sublingual Dosing
For adults and adolescents ≥12 years: administer 1-2 tablets (0.125 mg each) sublingually three to four times daily, 30-60 minutes before meals and at bedtime, with dosing intervals adjustable to every 4 hours as needed, not exceeding 12 tablets (1.5 mg) in 24 hours 1.
Standard Dosing Regimen
The FDA-approved sublingual formulation contains 0.125 mg hyoscyamine sulfate per tablet 1. The medication can be taken with or without water and is completely absorbed via the sublingual route 1.
Adult Dosing (≥12 years)
- Initial dose: 1-2 tablets (0.125-0.25 mg) sublingually
- Frequency: Three to four times daily
- Timing: 30-60 minutes before meals and at bedtime
- Maximum: 12 tablets (1.5 mg) per 24 hours
- Dose adjustment: May increase frequency to every 4 hours as needed 1
Geriatric Considerations
Elderly patients may be more sensitive to the usual adult dose and require dose reduction 1. Start at the lower end of the dosing range (1 tablet rather than 2) and monitor closely for anticholinergic side effects.
Pharmacokinetic Profile
Hyoscyamine is completely absorbed via sublingual administration, with rapid distribution throughout the body and disappearance from blood 1. The sublingual route bypasses first-pass hepatic metabolism, potentially improving bioavailability compared to oral administration 2. The majority of the drug is excreted unchanged in urine within 12 hours, with only trace amounts appearing in breast milk 1.
Clinical Context and Mechanism
Hyoscyamine sulfate is an anticholinergic/antispasmodic agent that is more potent than atropine in both central and peripheral effects 1. It works by:
- Inhibiting gastrointestinal propulsive motility
- Decreasing gastric acid secretion
- Controlling excessive pharyngeal, tracheal, and bronchial secretions 1
Special Clinical Applications
Palliative Care Setting
In palliative care for managing secretions or diarrhea, hyoscyamine 0.125 mg PO/ODT/SL every 4 hours as needed (maximum 1.5 mg/day) is recommended 3. This aligns with the FDA dosing but emphasizes the PRN nature for symptom control in end-of-life care.
Pediatric Dosing
The provided evidence does not contain specific pediatric dosing for hyoscyamine sulfate sublingual tablets. The FDA label only addresses patients ≥12 years 1.
Important Caveats
Anticholinergic side effects are dose-dependent and include dry mouth (xerostomia), urinary retention, constipation, blurred vision, tachycardia, and confusion (especially in elderly patients). Monitor for these effects and adjust dosing accordingly.
The sublingual formulation allows for rapid onset of action, making it suitable for acute symptom management while maintaining the option for scheduled dosing in chronic conditions requiring regular anticholinergic therapy.